Unknown

Dataset Information

0

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.


ABSTRACT: We have studied in vivo responses of "spontaneous" Brca1- and p53-deficient mammary tumors arising in conditional mouse mutants to treatment with doxorubicin, docetaxel, or cisplatin. Like human tumors, the response of individual mouse tumors varies, but eventually they all become resistant to the maximum tolerable dose of doxorubicin or docetaxel. The tumors also respond well to cisplatin but do not become resistant, even after multiple treatments in which tumors appear to regrow from a small fraction of surviving cells. Classical biochemical resistance mechanisms, such as up-regulated drug transporters, appear to be responsible for doxorubicin resistance, rather than alterations in drug-damage effector pathways. Our results underline the promise of these mouse tumors for the study of tumor-initiating cells and of drug therapy of human cancer.

SUBMITTER: Rottenberg S 

PROVIDER: S-EPMC1914039 | biostudies-literature | 2007 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

Rottenberg Sven S   Nygren Anders O H AO   Pajic Marina M   van Leeuwen Fijs W B FW   van der Heijden Ingrid I   van de Wetering Koen K   Liu Xiaoling X   de Visser Karin E KE   Gilhuijs Kenneth G KG   van Tellingen Olaf O   Schouten Jan P JP   Jonkers Jos J   Borst Piet P  

Proceedings of the National Academy of Sciences of the United States of America 20070711 29


We have studied in vivo responses of "spontaneous" Brca1- and p53-deficient mammary tumors arising in conditional mouse mutants to treatment with doxorubicin, docetaxel, or cisplatin. Like human tumors, the response of individual mouse tumors varies, but eventually they all become resistant to the maximum tolerable dose of doxorubicin or docetaxel. The tumors also respond well to cisplatin but do not become resistant, even after multiple treatments in which tumors appear to regrow from a small f  ...[more]

Similar Datasets

| S-EPMC10542309 | biostudies-literature
| S-EPMC102082 | biostudies-literature
2015-07-07 | GSE70541 | GEO
2015-07-07 | E-GEOD-70541 | biostudies-arrayexpress
| S-EPMC7518105 | biostudies-literature
| S-EPMC2929908 | biostudies-literature
| S-EPMC2937099 | biostudies-literature
| S-EPMC3717796 | biostudies-literature
| S-EPMC4741923 | biostudies-literature
| S-EPMC3444454 | biostudies-literature